RITUXIMAB: NEW POTENTIALITIES OF THERAPY FOR RHEUMATOID ARTHRITIS
Some patients with rheumatoid arthritis (RA) are unresponsive or intolerant to both synthetic first-line anti-inflammatory drugs (FLAID) and tumor necrosis factor (TNF) а inhibitors already included into all the treatment standards . Along with the conventional methods for overcoming drug resistance...
Main Authors: | D E Karateev, D E Karateyev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2008-12-01
|
Series: | Современная ревматология |
Online Access: | https://mrj.ima-press.net/mrj/article/view/197 |
Similar Items
-
THE EFFICACY AND SAFETY OF RITUXIMAB IN RHEUMATOID ARTHRITIS: NEW EVIDENCE
by: D. A. Kusevich, et al.
Published: (2017-09-01) -
Rituximab in the treatment of rheumatoid arthritis.
by: Taylor, P
Published: (2007) -
The Impact of Rituximab Therapy on the Chromosomes of Patients with Rheumatoid Arthritis
by: Šekib Sokolović, et al.
Published: (2010-05-01) -
THE ROLE OF LABORATORY BIOMARKERS IN PREDICTING THE EFFICIENCY OF RITUXIMAB THERAPY FOR RHEUMATOID ARTHRITIS: NEW EVIDENCE
by: A. S. Avdeeva, et al.
Published: (2017-07-01) -
USE OF TUMOR NECROSIS FACTOR-A INHIBITORS IN RHEUMATOID ARTHRITIS: TOPICAL ASPECTS
by: E L Luchikhina, et al.
Published: (2008-12-01)